REG - Venture Life Group - Directorate Changes

Venture LifeAnnouncement

17/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220517:nRSQ6837La&default-theme=true

RNS Number : 6837L  Venture Life Group PLC  17 May 2022

17(th) May 2022

 

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Group")

Directorate Changes

 

Venture Life (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the self-care market, announces the appointment
of Mr Paul McGreevy as Non-executive Chair of the Company with immediate
effect and consequent stepping down from the Board of Dr. Lynn Drummond.

Mr McGreevy is an experienced and successful executive with over 30 years
commercial experience in the consumer healthcare and products industry. He has
a strong track record of demonstrating commercial success in Omni-channel
sales across FMCG and is experienced in franchise, wholesale and
manufacturing, as well as having established credentials in internationalising
consumer products and businesses.

Mr McGreevy spent his early career with Walgreen Boots Alliance in the UK in
R&D, sales, and marketing between 1993 & 1999. This was followed by a
period at Dewhirst Group as R&D and Commercial Director. He joined The
Body Shop International in 2004 as Global Product Director, then moving on to
become Global Operations Director, having additional responsibilities of
R&D, acquisitions and divestments. During his 10 years at The Body Shop,
he had responsibilities to over 70 markets and oversaw significant growth and
expansion of the business.

Since leaving The Body Shop, Mr McGreevy has pursued a successful
Non-executive career, as both Chair and Non-executive Director of several
international consumer product businesses. He has current board appointments
in consumer businesses with a focus on brand, product development, operations,
and R&D, with Danish retail chain, Normal A/S, and cosmetics manufacturing
company, SnJ International Limited, whilst also also running his own
consultancy business, McGreevy Consulting Ltd.

 

Jerry Randall, CEO of Venture Life commented: "We are delighted to have Paul
join the Board of Venture Life Group as our new Non-executive Chair. His
extensive experience in the international consumer healthcare market will be
invaluable to us. In particular, Paul's knowledge of the omni-channel approach
to sales and marketing is very pertinent to us as we seek to grow our brands
and our business through the many channels available to us in today's market.
As an experienced board Director and Chair, Paul brings additional and
considerable governance experience to our Board, and we look forward to
working with him.

On behalf of the whole Board, I also extend our deepest thanks and gratitude
to our outgoing Chair, Dr Lynn Drummond. Lynn has been with us since before
our IPO in 2014 and has helped us navigate the difficult path of becoming a
growing and sustainably profitable consumer healthcare business on the public
markets.  We thank Lynn for her time with us and wish her all the very best
for the future.

Paul McGreevy commented: "I am very excited to join such an ambitious team,
with a great portfolio of brands that provides a solid foundation to
accelerate our growth in the self-care sector. VLG is well placed in a growing
market to further develop its brands, expand through acquisition, and increase
its international footprint."

 

Further information on Paul McGreevy

Paul Brian McGreevy (aged 54) has held the following directorships in the past
5 years:

Current Directorships:

·    McGreevy Consulting Ltd

·    S&J International (UK) Limited

·    Normal A/S

Previous Directorships held in the past 5 years:

·    Age UK Lancashire

·    Kennelpak Group Ltd

·    Kennelpak Holdings Ltd

There is no further information on Paul McGreevy required to be disclosed
under Schedule Two, paragraph (g) of the AIM Rules for Companies.

 

For further information, please contact:

 

 Venture Life Group PLC                              +44 (0) 1344 578004
 Jerry Randall, Chief Executive Officer

 Daniel Wells, Chief Financial Officer

 Cenkos Securities plc (Nomad and Joint Broker)      +44 (0) 20 7397 8900
 Michael Johnson/Russell Kerr (Sales)

 Stephen Keys/Camilla Hume (Corporate Finance)

 Singer Capital Markets (Joint Broker)               +44 (0) 20 7496 3000
 Jonathan Dighe (Sales)

 Shaun Dobson/Alaina Wong (Corporate Finance)

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in the UK, Italy, The Netherlands and
Sweden, the Group's product portfolio includes some key products such as the
UltraDEX and Dentyl oral care product ranges, the Balance Active range in the
area of women's intimate healthcare, the Lift and Glucogel product ranges for
hypoglycaemia, products for fungal infections and proctology, and
dermo-cosmetics for addressing the signs of ageing. Its products are sold in
over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples. In the UK and The Netherlands these are supplied direct by the
company to retailers, elsewhere they are supplied by the Group's international
distribution partners.

Through its two Development & Manufacturing operations in Italy and
Sweden, the Group also provides development and manufacturing services to
companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAKZGMKVVNGZZM